
In a little noticed order, a federal judge recently raised the intriguing possibility that a so-called patent thicket — a large number of patents that a drug maker obtains to thwart rivals — might stifle competition if the patents were established as the result of some misbehavior.
The order was issued last month in a lawsuit filed by AbbVie (ABBV), which is seeking to prevent Boehringer Ingelheim from marketing a biosimilar version of its Humira rheumatoid arthritis treatment. The medicine generated nearly $12.4 billion in sales last year in the U.S. alone for AbbVie and is protected by dozens of patents, many of which do not expire until 2022.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
@Observer079: I think you’re mixed up. What makes patent settlements “pay for delay” or “reverse payments” is that the patent-holder ends up paying the alleged infringer while proclaiming (through settlement) the validity of the patent. The contention is that this happens because the patent-holder splits the monopoly profits off the extended patent term for an invalid patent. If, as here, the infringer is paying the patent-holder for entry before patent expiration, that’s decidedly NOT a pay for delay situation and there’s no inference to be drawn that the patent is invalid.
HH10, I don’t question your explanation – what I surmise is they are not deferring merely out of the goodess of their hearts – and that the future royalties will reimburse whatever they are getting from AbbVee to hold off. Or, as you say, I may just be mixed up.
Hmmm, AbbVee denies paying to delay. Assuming this sentence by our scribe is accurate -, “Both companies agreed not to launch biosimilars in the U.S. until 2023, and will pay royalties to AbbVie.” – this seems to argue precisely for that. It reminds one of the current ‘collusion in plain sight’ dialectic.